EUCTR2006-004022-87-DK进行中（未招募）不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORS
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Pfizer Inc.
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically proven diagnosis of well-differentiated pancreatic islet
- •cell tumor (according to WHO 2000 classification.)19
- •2. Local, locally-advanced or metastatic disease documented as having shown
- •progression (per RECIST guidelines) on a scan (CT, MRI, or Octreoscan®) taken
- •within 12 months prior to baseline compared to a previous scan taken at any time in
- •the past (ie, patient must have had disease progression within the past year). The
- •recent scan indicating progression must not be the screening scan.1 Octreoscan
- •results may be used to document progressive disease prior to study entry, but not for RECIST determination of tumor response during the study.
- •3. Disease that is not amenable to surgery, radiation, or combined modality therapy with curative intent.
- •4. Presence of at least one measurable target lesion for further evaluation according to RECIST criteria (contrast enhancing lesion with the largest diameter =20 mm, based
- •on conventional CT or MRI scan (or =10 mm with spiral CT scan) done within 3 weeks before the start of treatment).
- •5. Adequate organ function as defined by the following:
- •Serum aspartate aminotransferase (AST; serum glutamate-oxalate transferase
- •[SGOT]) and serum alanine aminotransferase (ALT; serum glutamate-pyruvate transferase [SGPT]) =2.5 x upper limit of normal (ULN). If liver function abnormalities are due to underlying malignancy, then AST and ALT may be =5 x ULN
- •Total serum bilirubin =1.5 x ULN
- •Prothrombin time (PT) and partial thromboplastin time (PTT) =1.5 x ULN
- •Serum albumin =3.0 g/dL
- •Absolute neutrophil count (ANC) =1500/µL
- •Platelets =100,000/µL
- •Hemoglobin =9.0 g/dL
- •Serum creatinine =1.5 x ULN
- •Serum amylase or lipase =2.0 x ULN
- •6. ECOG Performance status 0 or 1.
- •7. Life expectancy = 3 months.
- •8. Age = 18 years.
- •9. Previous treatments with chemotherapy, loco-regional therapy (eg, chemoembolization) or interferon are permitted providing that toxicity has resolved to < Grade 1 at study entry and that last treatment was at least 4 weeks prior to baseline assessment.
- •10. Able to swallow oral compound.
- •11. Signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial prior to enrolment.
- •12. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Patients with poorly-differentiated pancreatic neuroendocrine tumors (according to
- •WHO 2000 classification).19
- •2. Current treatment with any chemotherapy, chemoembolization therapy, immunotherapy, or investigational anticancer agent other than somatostatin analogues.
- •3. Prior treatment with any tyrosine kinase inhibitors or anti-VEGF angiogenic
- •inhibitors. Prior treatment with non-VEGF-targeted angiogenic inhibitors is permitted.
- •4. Diagnosis of any second malignancy within the last 5 years, except for adequately
- •treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix uteri.
- •5. Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days, respectively prior to study drug administration
- •6. Pre-existing abnormality of thyroid function with TSH that cannot be maintained in the normal range with medication.
- •7. Concomitant treatment with therapeutic doses of anticoagulants. Low dose warfarin (Coumadin®) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed.
- •8. Unstable systemic diseases including uncontrolled hypertension (>150/100 mmHg
- •despite optimal medical therapy) or active uncontrolled infections.
- •9. Current treatment on another clinical trial.
- •10. Any of the following within the 12 months prior to study drug administration:
- •myocardial infarction, severe/unstable angina, symptomatic congestive heart failure,
- •cerebrovascular accident or transient ischemic attack, or pulmonary embolism.
- •11. Abnormal cardiac function with abnormal 12 lead ECG. Ongoing cardiac
- •dysrhythmias of NCI CTC grade =2, atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- •12. Symptomatic brain metastases, spinal cord compression, or new evidence of brain or leptomeningeal disease
- •13. Left ventricular ejection fraction (LVEF) =50% as measured by either multigated
- •acquisition (MUGA) scan or echocardiogram (ECHO).
- •14. Currently pregnant or breastfeeding. All female patients with reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to starting study drug. Both female and male patients must be surgically sterile or (or postmenopausal for females), or must agree to use effective contraception during the period of therapy. The definition of effective contraception will be based on the
- •judgment of the investigator or a designated associate, but examples include the
- •following: for women - implants, injectables, combined oral contraceptives,
- •intrauterine devices (IUDs), sexual abstinence, or a partner who has been
- •vasectomized for at least 6 months. For males - having had a vasectomy for at least 6 months, sexual abstinence, or condoms plus spermacide.
- •15. Positive test for human immunodeficiency virus (HIV) or acquired immunodeficiencysyndrome (AIDS) related illness.
- •16. Other severe acute or chronic medical or psychiatric condition or laboratory
- •abnormality that may increase the risk associated with study participation or study
- •drug administration, or may interfere with the interpretation of study results, and in
- •the judgment of the investigator would make the patient inappropriate for entry into
- •this study.
研究者
相似试验
进行中（未招募）
不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSEUCTR2006-004022-87-DEPfizer Inc.340
进行中（未招募）
1 期
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-BEPfizer Inc.340
进行中（未招募）
1 期
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-GBPfizer Inc.340
进行中（未招募）
不适用
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-NLPfizer Inc.340
进行中（未招募）
1 期
A PHASE III RANDOMIZED, DOUBLE-BLIND STUDY OF SUNITINIB (SU011248, SUTENT®) VERSUS PLACEBO IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC WELL-DIFFERENTIATED PANCREATIC ISLET CELL TUMORSProgressive, advanced/metastatic well-differentiated pancreatic islet cell tumoursMedDRA version: 9.1Level: HLTClassification code 10033632Term: Pancreatic neoplasmsEUCTR2006-004022-87-FRPfizer Inc.340